Stocksigma LogoStocksigma Logo

Piramal Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)

■ Revenue: 2,617 (+28.1% YoY | +15.3% QoQ) ■ EBITDA: 349 (+119.8% YoY | +78.7% QoQ) ■ EBITDA Margin (%): 13.3 (+556 bps YoY | +473 bps QoQ) ■ PAT: 5.6

Piramal Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)

Piramal Pharma Ltd · Outcome · 28 Oct 2026, 2:23 am

Piramal Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 2,617 (+28.1% YoY | +15.3% QoQ) ■ EBITDA: 349 (+119.8% YoY | +78.7% QoQ) ■ EBITDA Margin (%): 13.3 (+556 bps YoY | +473 bps QoQ) ■ PAT: 5.6 (Loss to Profit YoY | Loss to Profit QoQ) ■ EPS (INR): 0.04 (Loss to Profit YoY | Loss to Profit QoQ)

Original exchange filing (PDF)

More announcements from Piramal Pharma Ltd

All Piramal Pharma Ltd announcements